Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Mechanical devices challenge diuretics-only approach to acute heart failure

Mechanical devices challenge diuretics-only approach to acute heart failure

New Capabilities

First-in-class lymphatic drainage catheter posts positive feasibility results as three device makers race to crack a problem drugs have not solved

December 31st, 2026: LYMPH-HF pivotal trial planned to begin

Overview

A catheter threaded into a vein in the neck pulled an average 6.8 kilograms of excess fluid out of 40 hospitalized heart failure patients without damaging their kidneys. Six months later, 82.5 percent were still alive and out of the hospital.

Acute heart failure kills almost one in four patients within a year of admission, and about 30 percent end up readmitted within 90 days. The DELTA-HF results, published May 10 in the European Journal of Heart Failure, point to a mechanical alternative to diuretics. Diuretics have been the standard for half a century.

Why it matters

Heart failure hospitalizations send roughly a third of patients back within 90 days. A new class of devices is trying to break that cycle.

Questions about this story

No questions yet — be the first to ask.

Play on this story Voices Debate Predict

Key Indicators

6.8 kg
Average fluid removed
Mean weight loss at hospital discharge for the 40 patients treated with the eLym System.
82.5%
Alive and out of hospital at 6 months
Freedom from heart-failure rehospitalization and death in DELTA-HF.
100%
Successful device deployment
The catheter reached and operated at its target site in every case attempted.
~30%
Typical 90-day readmission rate
The persistent problem that drug therapy alone has not solved.
40
Patients in DELTA-HF
Single-arm feasibility study. The randomized LYMPH-HF pivotal trial begins later in 2026.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

Play

Exploring all sides of a story is often best achieved with Play.

Log in to play. Track your picks, climb the leaderboards. Log in Sign Up
Predict 4 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play
Timeline Five events from this story — drag them oldest to newest. Log in to play
Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

William Brangham
William Brangham
Professor of Medicine at The Ohio State University Wexner Medical Center
 Jorge Nuche
Jorge Nuche
Cardiologist at Hospital Universitario 12 de Octubre, Madrid

Organizations Involved

WhiteSwell
WhiteSwell
Medical device company
Sponsor of the DELTA-HF and upcoming LYMPH-HF trials

Galway-based medical device firm developing a catheter that drains excess lymphatic fluid through the thoracic duct.
Reprieve Cardiovascular
Reprieve Cardiovascular
Medical device company
Direct competitor in the acute-heart-failure decongestion space

Maker of an automated diuresis system that times IV saline and diuretic delivery to speed safe fluid removal.
AquaPass Medical
AquaPass Medical
Medical device company
Direct competitor pursuing a non-invasive decongestion approach

Maker of a wearable garment that uses warm air to evaporate fluid through the skin.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal agency
Has granted Breakthrough Device Designation to multiple decongestion devices

The U.S. regulator that approves medical devices for sale in the country.

Timeline

September 2007 December 2026

7 events Latest: December 31st, 2026
Tap a bar to jump to that date

  1. LYMPH-HF pivotal trial planned to begin

    Latest Clinical Trial

    WhiteSwell plans to start its randomized confirmatory trial across the U.S., Canada, Europe, and Israel later in 2026.

  2. DELTA-HF primary results released

    Clinical Trial

    WhiteSwell reports 6.8 kg average fluid loss, 100 percent deployment success, and 82.5 percent freedom from death and rehospitalization at 6 months in 40 patients.

  3. CVRx starts BENEFIT-HF for Barostim

    Clinical Trial

    A separate 2,500-patient trial begins enrolling to test whether a neck-implanted nerve stimulator cuts heart-failure death. Different mechanism, same patient pool as the decongestion devices.

  4. FASTR pilot meets primary endpoints

    Clinical Trial

    Reprieve Cardiovascular's automated diuresis system shows faster sodium and fluid removal versus standard diuretic therapy in 96 patients at THT 2025.

  5. WhiteSwell publishes DELTA-HF design

    Publication

    European Journal of Heart Failure publishes the rationale for testing thoracic-duct drainage in acute heart failure.

  6. CARRESS-HF reverses momentum for ultrafiltration

    Clinical Trial

    A larger NIH-funded trial shows ultrafiltration is no better than a stepped diuretic protocol and worsens kidney function. The result sets the device field back by years.

  7. UNLOAD trial favors ultrafiltration over diuretics

    Clinical Trial

    A 200-patient randomized study finds the Aquadex ultrafiltration device removes more fluid and cuts 90-day readmissions versus IV diuretics, opening the door to mechanical decongestion.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

September 2007

UNLOAD trial validates ultrafiltration (2007)

A 200-patient randomized trial published in the Journal of the American College of Cardiology compared the Aquadex ultrafiltration device against intravenous diuretics in hospitalized heart failure patients. The device group lost more weight at 48 hours and had fewer rehospitalizations at 90 days. CHF Solutions, the device's maker, gained early commercial traction.

Then

Ultrafiltration entered U.S. hospitals as an option for diuretic-resistant patients. Investment in mechanical decongestion accelerated.

Now

Aquadex still exists, now owned by Nuwellis, but adoption stayed modest. The single positive trial was not enough to displace diuretics from first-line care.

Why this matters now

DELTA-HF sits in the same niche UNLOAD opened. WhiteSwell is making the same bet that a device can do what diuretics cannot, while trying to avoid the pitfalls that limited Aquadex.

November 2012

CARRESS-HF stalls the device field (2012)

An NIH-funded randomized trial of 188 patients with worsening kidney function tested ultrafiltration against a stepped diuretic protocol. Published in the New England Journal of Medicine, it found ultrafiltration was no better at fluid removal and caused more kidney injury and adverse events.

Then

Enthusiasm for ultrafiltration collapsed almost overnight. Insurance coverage tightened and many programs shelved their devices.

Now

For nearly a decade, no major sponsor pursued a fresh device-based decongestion trial. The current wave of WhiteSwell, Reprieve, and AquaPass studies is the first serious return to the question.

Why this matters now

This is the cautionary tale every investor in the current wave knows. A positive feasibility trial in 40 patients can flip when a real control arm and 200 patients show up. LYMPH-HF must clear a bar that ultrafiltration could not.

May 2014

CardioMEMS wins FDA approval (2014)

The FDA approved the CardioMEMS HF System, a small pressure sensor implanted in the pulmonary artery to monitor fluid status remotely. The CHAMPION trial had shown a 28 percent reduction in heart failure hospitalizations. William Abraham, who later led DELTA-HF, was a principal investigator on CHAMPION.

Then

CardioMEMS became the first FDA-approved implantable hemodynamic monitor for heart failure. Abbott acquired the technology in 2017.

Now

Use grew slowly because of reimbursement and patient selection issues, but the device established that targeted device-based interventions could cut rehospitalizations enough to win approval.

Why this matters now

CardioMEMS shows the regulatory path is open for a heart failure device whose primary endpoint is fewer hospitalizations rather than fewer deaths. That is the path the new decongestion devices are trying to follow.

Sources

(7)
+1
GlobeNewswire Health Technology Net European Journal of Heart Failure Cardiac Interventions Today TCTMD Journal of Cardiac Failure GlobeNewswire